Surprising SanBio/Sumitomo Stroke Stumble Slams Stocks

Mesenchymal stem cell-based therapy's missed Phase IIb endpoint in stroke prompts both an assessment of future development plans and a precipitous fall in developers' stocks.

Memory loss and brain aging due to dementia and alzheimer's disease as a medical icon of a group of color changing autumn fall trees shaped as a human head losing leaves on a white background.
Phase II Failure For Novel Stroke Therapy • Source: Shutterstock

Failed clinical trials may be routine in the pharma world, but one such event has had a broad impact in Japan this week, amplified by recent meteoric rises in the product developer's stock and positive local sentiment around cell-based therapies.

An announcement by Tokyo-based venture SanBio Co. Ltd. that its regenerative medicine SB623 missed the primary efficacy endpoint in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

More from Focus On Asia